Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. 2002

Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
Division of Pharmacy, Chiba University Hospital, Chuo-ku, Chiba, Japan.

In the present study, we investigated the effects of 14 endogenous steroids on the CYP3A4-mediated drug metabolism by human liver microsomes in vitro. Nevirapine (NVP) 2-, 12-hydroxylations, carbamazepine (CBZ) 10,11-epoxidation, triazolam (TZM) 1'-, 4-hydroxylations, erythromycin (EM) N-demethylation, and 2-sulphamoylacetylphenol (SMAP) formation from zonisamide (ZNS) were investigated. The activities of the NVP 2-, 12-hydroxylations, the CBZ 10,11-epoxidation, and the TZM 4-hydroxylation were activated by endogenous androgens, such as androstenedione (AND), testosterone, and dehydroepiandrosterone. However, these androgens inhibited EM N-demethylation, TZM 1'-hydroxylation, and SMAP formation. To understand the mechanisms of these effects of androgens on CYP3A4 activities, we performed a kinetic analysis of the metabolism of CBZ and ZNS in the presence or absence of AND using the modified two-site equation model. The addition of AND to the reaction mixture caused a drastic increase in the activity of CBZ 10,11-epoxidase, especially at a low substrate concentration, and resulted in a change in the kinetics from the sigmoid to Michaelis-Menten type. On the other hand, the metabolism of ZNS was strongly inhibited by AND, although no allosteric change was observed in this case. These data demonstrate that endogenous steroids, especially androgens, strongly affect CYP3A4-mediated drug metabolism in vitro. The postulated mechanisms of the interactions between AND and CBZ or ZNS are discussed.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D004852 Epoxy Compounds Organic compounds that include a cyclic ether with three ring atoms in their structure. They are commonly used as precursors for POLYMERS such as EPOXY RESINS. Epoxide,Epoxides,Epoxy Compound,Oxiranes,Compound, Epoxy,Compounds, Epoxy
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat

Related Publications

Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
January 2007, Acta pharmacologica Sinica,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
January 2002, Drug metabolism and pharmacokinetics,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
September 1996, Drug metabolism and disposition: the biological fate of chemicals,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
January 2016, Drug metabolism letters,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
March 2015, European journal of drug metabolism and pharmacokinetics,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
July 1998, Journal of pharmaceutical sciences,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
October 1999, Xenobiotica; the fate of foreign compounds in biological systems,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
December 2001, European journal of clinical pharmacology,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
December 2001, International journal of clinical pharmacology and therapeutics,
Hiroyoshi Nakamura, and Hiromitsu Nakasa, and Itsuko Ishii, and Noritaka Ariyoshi, and Takashi Igarashi, and Shigeru Ohmori, and Mitsukazu Kitada
September 1971, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!